drugset / Trial / NCT07169552
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
NaSingle-groupOpen-labelTreatment
Summary
Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%)
Timeline
- Start
- 2025-12-09
- Primary completion
- 2026-12-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HC010 | Unknown | — | Intravenous |